Fig. 9: Irgm1-deficient macrophage-derived medium promotes osteogenic differentiation of BMSCs.
From: Targeting Irgm1 to combat osteoporosis: suppressing ROS and restoring bone remodeling
A Schematic diagram showed RAW264.7 cells under different conditions. B CCK8 assay detected BMSCs viability with different percentages of conditioned medium of RAW264.7 cells for the indicated times (n = 3). C, D ALP staining (C) and ALP activity (D) of BMSCs under various treatments for 7 days. Cells were stimulated as previously described. E, F ALP and alizarin red stain (E) and ALP activity (F) of BMSCs under different conditions. BMSCs were cultured in OIM with 20% conditioned medium from transfected RAW264.7 cells for 7 days (E, upper panel) or 21 days (E, lower panel). G WB analysis of Col1a1, Runx2, and Bmp2 expression in BMSCs treated with OIM containing 20% conditioned medium from transfected RAW264.7 cells for 5 days. H–J Quantitative analysis of Col1a1 (H), Runx2 (I), and Bmp2 (J) from (G) were normalized to GAPDH and presented as means ± SD (n = 3). ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs the indicated groups. K WB analysis of the level of CD206 and CD86 in RAW264.7 cells. L, M Quantitative analysis of CD206 (L) and CD86 (M) from (K) were normalized to GAPDH and presented as means ± SD (n = 3). ∗p < 0.05 and ns vs the indicated groups.
